# Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/oral-semaglutide-50-mg-taken-once-per-day-in-adults-with-overweight-or-obesity/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Filip K. Knop,Vanita R. Aroda,Ruben D do Vale,Thomas Holst‐Hansen,Peter Nørkjær Laursen,Julio Rosenstock,Domenica Rubino,W. Timothy Garvey |
| Citations | 389 |
| DOI | 10.1016/s0140-6736(23)01185-6 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4381953540 |
| PMID | 37385278 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Julio Rosenstock](https://scholariq.org/researchers/julio-rosenstock/)
- [Thomas Holst‐Hansen](https://scholariq.org/researchers/thomas-holst-hansen/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.